ADMA Biologics (NASDAQ:ADMA) Posts Quarterly Earnings Results, Meets Estimates

ADMA Biologics (NASDAQ:ADMA) released its quarterly earnings data on Wednesday. The biotechnology company reported $0.19 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.19, FiscalAI reports. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm had revenue of $114.49 million during the quarter, compared to analyst estimates of $139.98 million.

Here are the key takeaways from ADMA Biologics’ conference call:

• Company reported strong profitability and cash generation in Q1 — adjusted net income rose 22% YoY, gross margin expanded to 71%, adjusted EBITDA was $59.7M, and operating cash flow was ~$58M with pro forma net leverage below 0.5x.
• ASCENIV is the operational growth engine with record demand and utilization (revenue +28% YoY), expanding prescriber adoption, and a recent pediatric label expansion that the company cites as a key catalyst.
• BIVIGAM sales fell ~54% YoY due to aggressive discounting from new entrants and distributor inventory/ordering shifts; management calls the disruption transitory but it materially pressured Q1 top line.
• Management narrowed visibility and withdrew longer-term guidance amid competitive uncertainty, setting 2026 revenue to $530M–$560M and raising near-term R&D/SG&A to support the pipeline, which could weigh on margins if competition persists.
• Pipeline progress — ADMA plans a Pre?IND for SG?001 this year, will present preclinical data soon, and estimates a potential $300M–$500M peak market while leveraging yield?enhanced manufacturing and diversified plasma sourcing.

ADMA Biologics Trading Down 1.7%

Shares of NASDAQ:ADMA traded down $0.17 during trading on Wednesday, reaching $10.08. 12,591,621 shares of the company were exchanged, compared to its average volume of 5,206,077. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The firm has a market capitalization of $2.40 billion, a PE ratio of 16.80 and a beta of 0.83. The business’s fifty day simple moving average is $12.39 and its 200-day simple moving average is $15.54. ADMA Biologics has a 12-month low of $7.21 and a 12-month high of $23.98.

Wall Street Analyst Weigh In

ADMA has been the topic of several analyst reports. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Mizuho cut their target price on ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. Canaccord Genuity Group started coverage on ADMA Biologics in a report on Monday, April 20th. They set a “buy” rating and a $21.00 price target on the stock. Zacks Research downgraded ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.67.

Insider Transactions at ADMA Biologics

In other news, Director Steve Elms bought 7,000 shares of ADMA Biologics stock in a transaction on Thursday, March 5th. The stock was acquired at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the acquisition, the director owned 2,038,730 shares of the company’s stock, valued at $31,946,899.10. This trade represents a 0.34% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the transaction, the chief operating officer directly owned 466,600 shares in the company, valued at approximately $7,292,958. The trade was a 2.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

A number of large investors have recently made changes to their positions in the business. Lido Advisors LLC boosted its position in ADMA Biologics by 3.8% in the fourth quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock valued at $312,000 after buying an additional 629 shares during the last quarter. Cim LLC grew its position in ADMA Biologics by 0.7% during the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock worth $1,341,000 after purchasing an additional 665 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of ADMA Biologics by 28.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 700 shares during the last quarter. Cerity Partners LLC lifted its holdings in shares of ADMA Biologics by 1.8% in the 2nd quarter. Cerity Partners LLC now owns 48,572 shares of the biotechnology company’s stock valued at $884,000 after buying an additional 869 shares during the period. Finally, Fieldview Capital Management LLC lifted its holdings in shares of ADMA Biologics by 7.3% in the 4th quarter. Fieldview Capital Management LLC now owns 21,708 shares of the biotechnology company’s stock valued at $396,000 after buying an additional 1,486 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics News Roundup

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: FDA label expansion broadens pediatric market for ASCENIV, increasing addressable patients and long?term upside for product sales. ADMA Biologics Gains FDA Approval for Expanded ASCENIV Label
• Positive Sentiment: Q1 operational strength: ASCENIV revenue grew ~28% Y/Y, adjusted net income and adjusted EBITDA both rose, and cash from operations was strong — evidence of durable demand and near-term cash generation. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Q1 reported EPS of $0.19 matched consensus but total revenue of $114.5M missed street estimates (~$140M), a mixed print that limited upside despite profitability metrics. View Press Release
• Negative Sentiment: ADMA lowered FY?2026 revenue guidance to $530M–$560M vs. consensus ~ $625M and withdrew long?term guidance, signaling a weaker top?line outlook and creating near?term downside risk to the stock. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• Negative Sentiment: Multiple securities?law firms announced investigations and encouraged investors to contact them over alleged misleading disclosures and the recent share decline — heightening litigation risk and investor uncertainty. ADMA Investor News – Rosen Law Firm Investigation BFA Law Investigation Notice

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.